Milestone 01 December 2017

20th Anniversary Focus

The Editor of Prostate Cancer and Prostatic Diseases is proud to share a selection of key papers that have published in the journal to celebrate 20 years of publication! These papers showcase the breadth of scope and coverage that this journal consistently delivers to its readers.

Check out the Editorial from the Editor-in-Chief, Dr. Stephen Freedland, reflecting on the journal's first 20 years!

20th Anniversary Focus

20 years—A retrospective of prostate cancer and prostatic diseases
- Stephen J Freedland
Editorial19 Dec 2017 Prostate Cancer and Prostatic Diseases
Increasing incidence of metastatic prostate cancer in the United States (2004–2013)
- A B Weiner
- R S Matulewicz
- E M Schaeffer
Original Article19 Jul 2016 Prostate Cancer and Prostatic Diseases
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result
- M J Donovan
- M Noerholm
- G A Brown
Original Article8 Sep 2015 Prostate Cancer and Prostatic Diseases
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer
- A J Pantuck
- C A Pettaway
- D Heber
Original Article14 Jul 2015 Prostate Cancer and Prostatic Diseases
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
- H H Cheng
- R Gulati
- E Y Yu
Original Article20 Jan 2015 Prostate Cancer and Prostatic Diseases
Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer
- M Valerio
- P D Stricker
- M Emberton
Original Article2 Sep 2014 Prostate Cancer and Prostatic Diseases
A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T study
- R Thomas
- M Williams
- P Bellamy
Original ArticleOpen Access11 Mar 2014 Prostate Cancer and Prostatic Diseases
Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard
- M Abd-Alazeez
- A Kirkham
- M Emberton
Original Article15 Oct 2013 Prostate Cancer and Prostatic Diseases
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy
- A E Ross
- F Y Feng
- E M Schaeffer
Original Article22 Oct 2013 Prostate Cancer and Prostatic Diseases
Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial
- P Cormie
- R U Newton
- D A Galvão
Original Article15 Jan 2013 Prostate Cancer and Prostatic Diseases
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
- C J Paller
- X Ye
- M A Carducci
Original Article12 Jun 2012 Prostate Cancer and Prostatic Diseases
Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006
- N Sathiakumar
- E Delzell
- M L Kilgore
Original Article15 Mar 2011 Prostate Cancer and Prostatic Diseases
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
- B Furusato
- S-H Tan
- I A Sesterhenn
Original ArticleOpen Access29 Jun 2010 Prostate Cancer and Prostatic Diseases
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database
- S J Freedland
- L L Bañez
- J W Moul
Original Article7 Jul 2009 Prostate Cancer and Prostatic Diseases
Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation
- D A Galvão
- D R Taaffe
- R U Newton
Original Article14 Oct 2008 Prostate Cancer and Prostatic Diseases
Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer
- D A Galvão
- D R Taaffe
- R U Newton
Review8 May 2007 Prostate Cancer and Prostatic Diseases
Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up
- S Erturhan
- A Erbagci
- A Ustun
Original Article22 Aug 2006 Prostate Cancer and Prostatic Diseases
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
- Y Liu
Review9 May 2006 Prostate Cancer and Prostatic Diseases
Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures
- GL Wright Jr
- LH Cazares
- A Vlahou
Paper10 May 2000 Prostate Cancer and Prostatic Diseases
Pathologic progression of autochthonous prostate cancer in the TRAMP model
- JR Gingrich
- RJ Barrios
- NM Greenberg
Paper21 May 1999 Prostate Cancer and Prostatic Diseases
Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia
- J Hammarsten
- B Högstedt
- D Mellström
Paper29 Apr 1998 Prostate Cancer and Prostatic Diseases

20th Anniversary Focus

20th Anniversary Focus

20 years—A retrospective of prostate cancer and prostatic diseases

Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result

A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer

A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T study

Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database

Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation

Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer

Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up

Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer

Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures

Pathologic progression of autochthonous prostate cancer in the TRAMP model

Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia

Search

Quick links